ArticleCells2022
Rhenium Perrhenate (
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Investigating the Impact of Curcumin on the Methylation of DNMT1, CDH1, SMG1, and WT1 Genes in the MIAPaCa2 Cell Line Using High-Resolution Melting Analysis Compared to Methylation-Specific PCR.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Microfluidics-based Polymeric Micro/Nanocarriers for Drug Delivery in Liver Cancer Treatment: Recent Advances, Outlooks, and Progress.Current topics in medicinal chemistry · 2026Review
- Extraction, Purification and Identification of Bovine Lung Peptides and Its Antioxidant Effects on HAntioxidants (Basel, Switzerland) · 2025Article
- Correction: Asadian et al. Rhenium Perrhenate (Cells · 2024Article
- Modeling the Synergistic Impact of Yttrium 90 Radioembolization and Immune Checkpoint Inhibitors on Hepatocellular Carcinoma.Bioengineering (Basel, Switzerland) · 2024Article
- Efficient Induction of Apoptosis in Lung Cancer Cells Using Bismuth Sulfide Nanoparticles.Iranian journal of biotechnology · 2024Article
- Circulating Tumor Cells as a Promising Tool for Early Detection of Hepatocellular Carcinoma.Cells · 2023Review
- Latest in Cellular Pathology Research.Cells · 2022Article
- Article
- Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question.Cancers · 2022Article
- Ultrasound Triggers Hypericin Activation Leading to Multifaceted Anticancer Activity.Pharmaceutics · 2022Article
- Article
- Conjugated Linoleic Acid Treatment Attenuates Cancerous features in Hepatocellular Carcinoma Cells.Stem cells international · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
Abstract
Recurrence in hepatocellular carcinoma (HCC) after conventional treatments is a crucial challenge. Despite the promising progress in advanced targeted therapies, HCC is the fourth leading cause of cancer death worldwide. Radionuclide therapy can potentially be a practical targeted approach to address this concern. Rhenium-188 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.